The Snowdome Foundation was formed in 2010 with a mission to accelerate next-generation treatments for Australian blood cancer patients to help them live longer, better lives. It aims to fast-track access to new blood cancer treatments by channelling government and private philanthropic investments into ground breaking research, clinical trials, and personalised therapies. In many cases, clinical trials are the last ‘hope’ for patients. There is no other Australian organisation supporting the treatment of blood cancers in this way.
Since inception, Snowdome has extended 40 research grants representing over $23 million to fund over 50 multi-year research positions. The Snowdome Foundation in collaboration with Maddie Riewoldt’s Vision received the inaugural National Charity award in the 2016 Telstra Australian Business Awards in recognition of their outstanding work. In 2018, Snowdome and Maddie Riewoldt’s Vision ranked #59 in Financial Times 1000: High-Growth Companies in Asia-Pacific.
The Snowdome Foundation is responsible for overseeing business, finance and administration governance for the ALA. The ALA operates within Snowdome’s governance framework and adhere to Snowdome Policies and Procedures, Code of Conduct and Ethics.
For further information about Snowdome visit www.snowdome.org.au